Atossa Therapeutics Q1 2024 Adj EPS $(0.05) Beats $(0.07) Estimate
Portfolio Pulse from Benzinga Newsdesk
Atossa Therapeutics reported Q1 2024 adjusted EPS losses of $(0.05), surpassing the analyst consensus estimate of $(0.07) by 28.57 percent.

May 13, 2024 | 12:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atossa Therapeutics reported better-than-expected Q1 2024 earnings, with losses per share of $(0.05) against an expected $(0.07).
Beating earnings estimates typically has a positive impact on a company's stock price in the short term as it indicates better financial health and performance than analysts expected. This positive surprise can lead to increased investor confidence and demand for the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100